Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Summary: Retatrutide is an investigational triple hormone receptor agonist peptide (GLP-1, GIP, and glucagon) developed by Eli Lilly for obesity treatment, currently in Phase 3 trials and not yet approved by the MHRA or EMA
Like Mounjaro, retatrutide is a GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide1) agonist
Binienda Z, Virmani A
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials
Check out the full piece: #ObesityCare #GLP1 #ChronicDisease #ValueBasedCare To view or add a comment, sign in Ilant Health founder and CEO Elina Onitskansky, alongside Bryan Sivak (former HHS CTO), just published an op-ed in Fortune tackling a binary problem in the GLP-1 debate: cover everything, or cover nothing
US$ 24.45
US$ 25.78
US$ 24.79
US$ 24.15
US$ 28.17
